Hollander Peter, Rostgaard Klaus, Smedby Karin E, Chang Ellen T, Amini Rose-Marie, de Nully Brown Peter, Glimelius Bengt, Adami Hans-Olov, Melbye Mads, Glimelius Ingrid, Hjalgrim Henrik
Am J Epidemiol. 2015 Oct 1;182(7):624-32. doi: 10.1093/aje/kwv081. Epub 2015 Sep 6.
Results from previous investigations have shown associations between the risk of Hodgkin lymphoma (HL) and a history of autoimmune and atopic diseases, but it remains unknown whether these associations apply to all types of HL or only to specific subtypes. We investigated immune diseases and the risk of classical HL in a population-based case-control study that included 585 patients and 3,187 controls recruited from October 1999 through August 2002. We collected information on immune diseases through telephone interviews and performed serological analyses of specific immunoglobulin E reactivity. Tumor Epstein-Barr virus (EBV) status was determined for 498 patients. Odds ratios with 95% confidence intervals were calculated using logistic regression analysis. Rheumatoid arthritis was associated with a higher risk of HL (odds ratio (OR) = 2.63; 95% confidence interval (CI): 1.47, 4.70), especially EBV-positive HL (OR = 3.18; 95% CI: 1.23, 8.17), and with mixed-cellularity HL (OR = 4.25; 95% CI: 1.66, 10.90). HL risk was higher when we used proxies of severe rheumatoid arthritis, such as ever having received daily rheumatoid arthritis medication (OR = 3.98; 95% CI: 2.08, 7.62), rheumatoid arthritis duration of 6-20 years (OR = 3.80; 95% CI: 1.72, 8.41), or ever having been hospitalized for rheumatoid arthritis (OR = 7.36; 95% CI: 2.95, 18.38). Atopic diseases were not associated with the risk of HL. EBV replication induced by chronic inflammation in patients with autoimmune diseases might explain the higher risk of EBV-positive HL.
以往的调查结果显示,霍奇金淋巴瘤(HL)风险与自身免疫性疾病和特应性疾病史之间存在关联,但这些关联是否适用于所有类型的HL或仅适用于特定亚型仍不清楚。在一项基于人群的病例对照研究中,我们调查了免疫疾病与经典HL风险之间的关系,该研究纳入了1999年10月至2002年8月招募的585例患者和3187例对照。我们通过电话访谈收集了免疫疾病信息,并对特异性免疫球蛋白E反应性进行了血清学分析。对498例患者确定了肿瘤爱泼斯坦-巴尔病毒(EBV)状态。使用逻辑回归分析计算了95%置信区间的比值比。类风湿性关节炎与HL风险较高相关(比值比(OR)=2.63;95%置信区间(CI):1.47,4.70),尤其是EBV阳性HL(OR = 3.18;95% CI:1.23,8.17),以及混合细胞性HL(OR = 4.25;95% CI:1.66,10.90)。当我们使用严重类风湿性关节炎的替代指标时,HL风险更高,例如曾接受每日类风湿性关节炎药物治疗(OR = 3.98;95% CI:2.08,7.62)、类风湿性关节炎病程为6至20年(OR = 3.80;95% CI:1.72,8.41)或曾因类风湿性关节炎住院(OR = 7.36;95% CI:2.95,18.38)。特应性疾病与HL风险无关。自身免疫性疾病患者慢性炎症诱导的EBV复制可能解释了EBV阳性HL风险较高的原因。